The panel discusses key learnings from recent studies in non-clear cell RCC subtypes and the need to better understand disease biology to develop optimized, histology-specific therapies rather than extrapolating clear cell treatment approaches.
A World of Research, Care, and Science: Becoming A Radiation Oncologist
James B. Yu, MD, MHS, FASTRO, didn’t always envision himself as a radiation oncologist, but now works tirelessly to treat patients and advance research for genitourinary cancers.
Finding Ways to Break the Mold in GU Oncology
Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.
Positive Efficacy Noted With Cemiplimab/Chemotherapy in Penile Carcinoma
The phase 2 EPIC trial assessing patients with penile carcinoma met its primary end point of clinical benefit rate, with the lower bound of the confidence interval exceeding the null hypothesis limit.
Oncology Peer Review On-The-Go: Value of Geriatric Assessment in Patients With Genitourinary Carcinomas
Lead author, Quirin Zangl, MD, spoke with CancerNetwork about research published in the journal ONCOLOGY focusing on the importance comprehensive geriatric assessment tools for patients with genitourinary carcinomas.
A Look at Upcoming Impactful Presentations at ASCO GU 2025
The 2025 Genitourinary Cancers Symposium will feature key updates in the management of different bladder, prostate, and kidney cancer populations.
Enfortumab Vedotin Combo Gains European Approval for Urothelial Cancer
The decision follows phase 3 EV-302 trial findings showing improved survival with enfortumab vedotin plus pembrolizumab vs chemotherapy in urothelial cancer.